ArticleHealth economics review2026

Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis.

Ziyad S Almalki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.